TTD Drug ID: DAP000475

Drug Information
Name	Minaprine
Synonyms	AC1L1HMV; Spectrum4_000418; D05039; M3157_SIGMA; IDI1_000063; Minaprina [INN-Spanish]; BSPBio_002909; NCGC00016795-01; KBioSS_001814; Prestwick1_000066; BPBio1_000277; Minaprinum; Spectrum5_001593; BRD-K02867583-300-05-5; CB 30038; MolPort-003-958-699; CHEBI:51038; CHEMBL278819; Cantor; DB00805; CAS-25953-17-7; SPBio_001454; 4-Methyl-3-(2-morpholinoethylamino)-6-phenylpyridazin; AR-1G3866; 4-methyl-N-(2-morpholin-4-ylethyl)-6-phenylpyridazin-3-amine; 25905-77-5; KBio2_001814; KBioGR_000716; EINECS 247-329-8; AB00053599; KBio3_002409; KBio2_004382; Spectrum2_001407; Spectrum3_001445; SPBio_002172; Cantor (TN); DivK1c_000063; Prestwick0_000066; CID4199; NINDS_000063; Minaprina; Brantur; L001202; Minaprine dihydrochloride; Prestwick3_000066; N-(4-Methyl-6-phenyl-3-pyridazinyl)-4-morpholineethanamine; Minaprinum [INN-Latin]; 25953-17-7 (di-hydrochloride); KBio2_006950; Minaprine (USAN/INN); KBio1_000063; Spectrum_001334; M3157_FLUKA; BSPBio_000251; Prestwick2_000066; minaprine; Minaprine [USAN:BAN:INN]; 4-Morpholineethanamine, N-(4-methyl-6-phenyl-3-pyridazinyl)-; ZINC19796082; 4-(2-((4-Methyl-6-phenyl-3-pyridazinyl)amino)ethyl)morpholine; AC1Q4YHU; AGR 1240; LS-92883; 3-(morpholinoethyl)amino-4-methyl-6-phenylpyridazine; NCGC00016795-02
Indication	Depression [ICD9: 311   ICD10: F32]			Approved    [1]
Structure	Click to save drug structure in 3D MOL format Click to save drug structure in 2D MOL format
InChI	1S/C17H22N4O/c1-14-13-16(15-5-3-2-4-6-15)19-20-17(14)18-7-8-21-9- 11-22-12-10-21/h2-6,13H,7-12H2,1H3,(H,18,20)
InChIKey	LDMWSLGGVTVJPG-UHFFFAOYSA-N
Canonical SMILES	CC1=CC(=NN=C1NCCN2CCOCC2)C3=CC=CC=C3
Therapeutic Class	Antidepressive Agents
CAS Number	CAS 25905-77-5
Formula	C17H22N4O
PubChem Compound ID	CID 4199.
PubChem Substance ID	SID 213627.
ChEBI	51038;
SuperDrug ATC ID	N06AX07
SuperDrug CAS ID	025905775;
Target	5-hydroxytryptamine 2B receptor			Antagonist	[2][3]
Ref 1	Novel cholinesterase inhibitors as future effective drugs for the treatment of Alzheimer's disease. Expert Opin Investig Drugs. 2006 Jan;15(1):1-12. To Reference
Ref 2	Mini Rev Med Chem. 2007 Nov;7(11):1108-19.Privileged structures: a useful concept for the rational design of new lead drug candidates. To Reference
Ref 3	Protective effect of minaprine against the abnormal changes of 2-deoxyglucose uptake by rat hippocampal slices induced by hypoxia/hypoglycemia. Jpn J Pharmacol. 1992 Sep;60(1):33-8. To Reference

Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.

Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore

All rights reserved.